

## Tokyo Future Style signs Distribution Agreement for Japan and Taiwan with TropiQ Health Sciences, a Dutch Bio Venture Company

**TROPiQ** HEALTH SCIENCES



Tokyo Future Style, Inc


Tokyo Future Style, Inc (Tsukuba City, Japan) and TropiQ Health Sciences (Nijmegen, the Netherlands) are pleased to announce having signed an agreement for distribution of TropiQ's proprietary unique drug discovery methods related to the vector bone diseases like mosquito transmission, such as Malaria, Dengue etc., in Japanese and Taiwanese market.



Vector-borne diseases are infectious diseases transmitted by insects such as mosquitoes, flies and ticks. Together they threaten half of the world's population and cause more than 1 million deaths annually. People in the poorest countries are the most vulnerable. For example, malaria

leads to over 250 million clinical cases and causes 600,000 deaths per year, mainly children under five years of age in sub-Saharan Africa. The disease is caused by a parasite and is transmitted by mosquitoes.

About another mosquitoes transmissible disease, Dengue infection, in 2014, two years ago, there occurred more than 100 people infection case by the domestic mosquitoes in a central park in Tokyo, that was really the new threat in our history. Further, in Taiwan, every year, Dengue transmission by mosquitoes is one of the biggest national social issue to be controlled by the government.



TropiQ's technology platform includes facilities for semi-automated cell and parasite culture, a vector lab for entomological experiments and liquid dispensing and state-of-the-art signal detection equipment. TropiQ has developed a unique barcoded live insect screening technology for discovery of novel

vector control agents (insecticides, repellents, attractants) and malaria transmission-blocking molecules.

## **Products and Services by TropIQ**

TropIQ provides services and reagents to accelerate the research. These include:

1. Barcoded microtiter-plate based live insect screening assays for discovery of vector control agents and antimalarials
2. Insecticide sensitivity screens in systemic and contact mode
3. Malaria life cycle fingerprinting. IC50 measurements against all *P. falciparum* stages, including gametocytes, oocysts, sporozoites and liver stage parasites.
4. Sensitive mix-and-measure immunoassays to determine malaria immune responses
5. Supply of wildtype and transgenic GFP/luciferase parasite stages for assay development and assay calibration
6. Supply of monoclonal antibodies against various epitopes of sexual stage antigens (Pfs48/45, Pfs25, Pfs230)

Tokyo Future Style, Inc is selling TropIQ's products (Monoclonal antibodies) and mediate their contract service for the territory of Japan and Taiwan.

---

### **About TropIQ Health Sciences**

TropIQ Health Sciences was founded in 2011 as a spin-off of the Radboud University Nijmegen Medical Center in the Netherlands. TropIQ combines world-class parasitological and entomological expertise with state of the art drug discovery technologies. Through this combination, TropIQ is uniquely positioned to accelerate the development of novel medicines, vaccines and vector control measures.

### **About Tokyo Future Style, Inc.**

Tokyo Future Style, Inc. is an international trading and marketing company located in the Tokyo area. TFS mission is to market and distribute novel and unique products and services from foreign biotech companies to academic and government institutions, and to research and development laboratories of major pharmaceutical, diagnostic and biotech companies in Japan and Taiwan.

---

Contact for this article:    Takashi Endo /CEO    Tokyo Future Style, Inc.  
   +81-29-851-9222    endo@tokyofuturestyle.com